Type: Anticancer Drug Developer: Novartis AG Location: Basel, Switzerland Website: www.novartis.com Indication(s): For the treatment of Ph+ chronic myelogenous leukemia, gastrointestinal stromal tumors, acute lymphoblastoid leukemia, chronic eosinophilic leukemia, myelodysplastic disease, aggressive systemic mastocytosis and dermatofibrosarcoma Approval Date: May 2001 Patent Expires: 2015 2008 Revenue: $3.700 billion Percentage of Novartis' Total Revenue: 8.92 percent Gleevec Targets

Proper Name: Infliximab Type: Anti-inflammatory Drug Developer: Centocor Inc. Location: Malvern, Pennsylvania Website: www.centocor.com Indication(s): For the treatment of moderately to severely active Crohn's disease, reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in patients with fistulizing Crohn's disease; for the treatment of active ankylosing spondylitis; for reducing signs and symptoms of active arthritis in patients with

Proper Name: Trastuzumab Type: Anticancer Drug Developer: Genentech Inc. Location: South San Francisco, California Website: www.gene.com Indication(s): To treat early and metastatic breast cancer in HER2-positive women, including combinations with chemotherapy, aromatase inhibitors and hormonal therapy Approval Date: September 1998 Patent Expires: 2019 Total 2008 Revenue (Reported by Roche Group): $4.394 billion 2008 Revenue Reported by Genentech: $1.382 billion Percentage of Roche

Proper Name: Bevacizumab Type: Anticancer Developer: Genentech Inc. Location: South San Francisco, California Website: www.gene.com Indication(s): First and second-line treatment of metastatic colorectal cancer in combination with intravenous 5-FU-based chemotherapy; first-line treatment of inoperable advanced, recurrent or metastatic non-squamous non-small-cell lung cancer, in combination with carboplatin and paclitaxel; first-line combination therapy with paclitaxel for advanced HER2

Proper Name: Adalimumab Type: Anti-inflammatory agent Developer: Abbott Location: Abbott Park, Illinois Website: www.abbott.com Indication(s): Forthe treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, polyarticular juvenile idiopathic arthritis and Crohn's disease Approval Date: December 2002 Patent Expires: 2018 2008 Revenue: $4.521 billion Percentage of Abbott's Total Revenue: 15.31 percent History of Humira Approved for five indications in

Proper Name: Rituximab Type: Anticancer, anti-inflammatory Drug Developer: Genentech Inc. Location: South San Francisco, California Website: www.gene.com Indication(s): For the treatment of relapsed or refractory low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), slow-growing NHL, aggressive NHL in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), to diffuse large B-cell lymphoma in combination with CHOP or other chemotherapy regimens, and in

Proper Name: Etanercept Type: Anti-inflammatory Drug Developer: Amgen Inc. Location: Thousand Oaks, California Website: www.amgen.com Indication(s): To reduce the signs and symptoms of moderate to severe rheumatoid arthritis, moderate to severe polyarticular juvenile rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, moderate to severe plaque psoriasis and pediatric chronic severe plaque psoriasis (8 years+) Approval Date: November 1998 Patent Expires: 2009, 2012 2008

On average, $1 billion, 10 years and a 30 percent success rate is the risk. Conversely, $7.5 billion to $30 billion in sales, and bragging-rights validation of your objective is the potential reward. That reward can be $50 billion and more, if a drugmaker decides to either develop a secondary therapeutic indication, or even a knock-off version of its own blockbuster drug by becoming a biogenerics developer as well. The threat from biotech's impending superstar drugs, personalized therapeutics